Related Experiment Video
Updated: Jul 31, 2025
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Fundamental concepts of protein therapeutics and spacing in oncology: an updated comprehensive review
Bahareh Farasati Far1, Maryam Safaei2, Fatemeh Mokhtari3
1Research Laboratory of Green Organic Synthesis and Polymers, Department of Chemistry, Iran University of Science and Technology, Narmak, Tehran, Iran.
Abstract:
Current treatment regimens in cancer cases cause significant side effects and cannot effectively eradicate the advanced disease. Hence, much effort has been expended over the past years to understand how cancer grows and responds to therapies. Meanwhile, proteins as a type of biopolymers have been under commercial development for over three decades and have been proven to improve the healthcare system as effective medicines for treating many types of progressive disease, such as cancer. Following approving the first recombinant protein therapeutics by FDA (Humulin), there have been a revolution for drawing attention toward protein-based therapeutics (PTs). Since then, the ability to tailor proteins with ideal pharmacokinetics has provided the pharmaceutical industry with an important noble path to discuss the clinical potential of proteins in oncology research. Unlike traditional chemotherapy molecules, PTs actively target cancerous cells by binding to their surface receptors and the other biomarkers particularly associated with tumorous or healthy tissue. This review analyzes the potential and limitations of protein therapeutics (PTs) in the treatment of cancer as well as highlighting the evolving strategies by addressing all possible factors, including pharmacology profile and targeted therapy approaches. This review provides a comprehensive overview of the current state of PTs in oncology, including their pharmacology profile, targeted therapy approaches, and prospects. The reviewed data show that several current and future challenges remain to make PTs a promising and effective anticancer drug, such as safety, immunogenicity, protein stability/degradation, and protein-adjuvant interactions.
Insights
Protein therapeutics (PTs) offer a targeted approach to cancer treatment, improving upon traditional chemotherapy. However, challenges like safety and immunogenicity must be addressed for PTs to become effective anticancer drugs.
Area of Science:
- Biotechnology
- Oncology
- Pharmacology
Background:
- Current cancer treatments have significant side effects and limitations in eradicating advanced disease.
- Protein therapeutics (PTs), developed over three decades, have emerged as effective medicines for progressive diseases, including cancer.
- The FDA approval of the first recombinant protein therapeutic marked a turning point, increasing interest in PTs for oncology.
Purpose of the Study:
- To analyze the potential and limitations of protein therapeutics (PTs) in cancer treatment.
- To highlight evolving strategies in PT development and application for oncology.
- To provide a comprehensive overview of the current state of PTs in cancer research.
Main Methods:
- Review of current literature on protein therapeutics in oncology.
- Analysis of pharmacology profiles and targeted therapy approaches for PTs.
- Evaluation of factors influencing the efficacy and safety of PTs.
Main Results:
- PTs offer targeted cancer cell destruction by binding to specific receptors, unlike traditional chemotherapy.
- The development of PTs allows for tailored pharmacokinetics, presenting a novel therapeutic avenue.
- Several challenges remain, including safety, immunogenicity, protein stability, and interactions with adjuvants.
Conclusions:
- Protein therapeutics show significant promise in oncology due to their targeted action and customizable nature.
- Addressing challenges such as safety, immunogenicity, and stability is crucial for realizing the full potential of PTs in cancer therapy.
- Continued research and evolving strategies are necessary to establish PTs as effective and reliable anticancer drugs.
More Related Videos
06:34Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Related Concept Videos
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:16Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
01:28Biopharmaceutics and Pharmacokinetics: Overview
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...